Innovative Hydrogen Therapy for Fighting Chronic Diseases
FIBROSIS
Recent estimates suggest that fibrotic disease is responsible for almost half of all deaths in Western developed countries.
Fibrosis affects nearly all tissues and organ systems.
Fibrosis is the end result of chronic inflammatory reactions induced by a variety of stimuli including autoimmune diseases, persistent infections, allergic responses, chemotherapy drugs (and some other drugs), radiation, chemical insults and tissue injury (physical or ischemic).
In the setting of ongoing (chronic) inflammatory stimulus, the normal wound healing process can be continuously activated leading to a chronic non-healing wound. As a result, rather than normal, healthy remodeled tissue, a fibrotic phenotype emerges.
Cancer is increasingly recognized as a fibrotic disease. Tumors often trigger a chronic wound-healing response that creates a dense, collagen-rich scar tissue (fibrosis) around cancer cells, which acts as a barrier to treatment and promotes tumor progression.
Fibrosis is a pathological feature of most chronic inflammatory diseases.
Most current therapeutic agents are destined to alleviate disease symptoms only- rather than curing the underlying conditions or stopping its progression.
The failure of numerous exogenous antioxidants to demonstrate efficiency against chronic inflammation and fibrosis in clinical trials is a well documented phenomenon despite promising preclinical results.
Exogenous antioxidants are compounds obtained from diet or supplements that protect cells against damage by neutralizing excessive ROS. Key examples include vitamins (C and E), carotenoids (beta-carotene, lycopene), polyphenols (resveratrol, flavonoids), trace elements (selenium, zinc), and compounds like N-acetylcysteine (NAC).
Lately Hydrogen emerged as a promising antioxidant agent for treating chronic inflammatory diseases.
